Clinical Trials Browser

Phase 2 × OTHER_GOV × sitravatinib × Clear all

NCT05407519 2023-03-22

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular